Dysport® (abobotulinumtoxinA) – New indication
August 1, 2016 – Ispen Biopharmaceuticals announced the FDA approval of Dysport (abobotulinumtoxinA) for injection for the treatment of lower limb spasticity in pediatric patients two years of age and older.
Download PDF
